Renerve Limited
RNV.ASXHealth Care
ReNerve specialises in developing a range of 'ready to use' products that are cleaner, safer and better for the repair or replacement of damaged peripheral nerves resulting in better patient outcomes.
Market Data
$0.083
+0.0%$13.8M
-100000.0x
$-0.032
0.00%
-0.4%
Latest Earnings
1HFY26 Appendix 4D and Half Year Report
26 February 2026
ReNerve Limited reported a 47.3% increase in losses to $2.7M for 1HFY26, despite growing sales revenue to $164K. The company raised $3.2M through a placement at $0.12 per share to fund accelerated sales and marketing activities, and expanded its product portfolio through a partnership with Berkeley Biologics while securing regulatory approvals in Asian markets. Key points: Sales revenue increased 60.2% to $164K driven by expanded commercial activities; Successfully raised $3.2M at $0.12 per share to fund accelerated sales and marketing activities; Launched Empliq tissue-based product range through strategic partnership with Berkeley Biologics
Recent Announcements
1HFY26 Appendix 4D and Half Year Report
ReNerve Limited reported a 47.3% increase in losses to $2.7M for 1HFY26, despite growing sales revenue to $164K. The company raised $3.2M through a placement at $0.12 per share to fund accelerated sales and marketing activities, and expanded its product portfolio through a partnership with Berkeley Biologics while securing regulatory approvals in Asian markets. Key points: Sales revenue increased 60.2% to $164K driven by expanded commercial activities; Successfully raised $3.2M at $0.12 per share to fund accelerated sales and marketing activities; Launched Empliq tissue-based product range through strategic partnership with Berkeley Biologics
Get real-time alerts for RNV
Receive AI-powered earnings summaries and instant notifications when Renerve Limited releases results.
Register Free